Entecavir Gains FDA Approval

Entecavir Gains

The FDA has approved entecavir (Baraclude™, Bristol-Myers Squibb) for the treatment of chronic hepatitis B infection in adults with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease. This oral antiviral therapy is designed to block the replication of hepatitis B virus in the body by interfering with the ability of the virus to infect cells.
canadian drugstore online